Univest
Univest
  • Markets
  • Sun Pharma vs Dr Reddy’s 2027: Profits Fell Over 30% at Both, Yet One Stock Sits Near Its 52-Week High

    • November 20, 2026
    • Posted by: Kunal Singla
    • Category: Market
    No Comments
    Sun Pharma vs Dr Reddy's 2027: Profits Fell Over 30% at Both, Yet One Stock Sits Near Its 52-Week High

    Sun Pharma vs Dr Reddy’s 2027: both reported Q2 FY27 profit declines of more than 30%, but Dr Reddy’s trades within 1% of its 52-week high while Sun Pharma is about 7% below. A side-by-side data comparison.

    read more
  • Aurobindo Pharma Analyst Review 2027: Record Quarter Lifts Targets Near ₹2,110

    • November 20, 2026
    • Posted by: Kunal Singla
    • Category: Market
    No Comments
    Aurobindo Pharma Analyst Review 2027: Record Quarter Lifts Targets Near ₹2,110

    Aurobindo Pharma posted a record Q2 FY27 with profit up about 33% to ₹1,124 crore, helped by Lannett, Europe and broad formulation growth. Geojit and Motilal Oswal set targets near ₹2,110 while Prabhudas Lilladher holds at ₹1,775. We review results, targets and risks for 2027.

    read more
  • AstraZeneca Pharma India Analyst Review 2027: Sales Jump 30% but Profit Lags and P/E Stays Near 86

    • November 20, 2026
    • Posted by: Chaitanya Auti
    • Category: Market
    No Comments
    AstraZeneca Pharma India Analyst Review 2027: Sales Jump 30% but Profit Lags and P/E Stays Near 86

    AstraZeneca Pharma India grew Q2 FY27 revenue 30% to ₹729 crore, helped by oncology and a fast-growing rare disease business, but net profit rose only 15%. With thin brokerage coverage and a P/E near 86, we review results, valuation and risks for 2027.

    read more
  • 3 Cancer Medicines Maker, Heritage Resorts Owner and Gas Field Operator Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation

    • November 19, 2026
    • Posted by: Chaitanya Auti
    • Category: Best Stocks
    No Comments
    3 Cancer Medicines Maker, Heritage Resorts Owner and Gas Field Operator Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation

    Oncology Generic, Resort and Gas Well Stocks with a strong future roadmap: Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation. Compare price, valuation, return on equity and revenue growth as of 17 November 2026.

    read more
  • Alpa Laboratories Analyst Review 2027: Sales Rise 10% but Q2 Swings to a Loss

    • November 19, 2026
    • Posted by: Chaitanya Auti
    • Category: Market
    No Comments
    Alpa Laboratories Analyst Review 2027: Sales Rise 10% but Q2 Swings to a Loss

    Alpa Laboratories grew Q2 FY27 sales about 10% to ₹32.22 crore but posted a loss of ₹1.85 crore as operating profit turned negative. The Indore drug maker trades at about 0.58 times book, near its 52-week low. With no brokerage coverage, we review results and risks.

    read more
  • Albert David Analyst Review 2027: Sales Up 16% and Margins Recover, Profit Back in Black

    • November 19, 2026
    • Posted by: Ankit Jaiswal
    • Category: Market
    No Comments
    Albert David Analyst Review 2027: Sales Up 16% and Margins Recover, Profit Back in Black

    Albert David grew Q2 FY27 sales 16% to ₹100.83 crore and returned to a ₹2.88 crore profit after a loss a year ago, as operating margin rose to 11.6%. The Kolkata drug maker trades near book value. With no brokerage coverage, we review results, the business and risks.

    read more
  • Alpa Laboratories Analyst Review 2027: Sales Rise 10% but Q2 Swings to a Loss

    • November 19, 2026
    • Posted by: Chaitanya Auti
    • Category: Market
    No Comments
    Alpa Laboratories Analyst Review 2027: Sales Rise 10% but Q2 Swings to a Loss

    Alpa Laboratories grew Q2 FY27 sales about 10% to ₹32.22 crore but posted a loss of ₹1.85 crore as operating profit turned negative. The Indore drug maker trades at about 0.58 times book, near its 52-week low. With no brokerage coverage, we review results and risks.

    read more
  • Albert David Analyst Review 2027: Sales Up 16% and Margins Recover, Profit Back in Black

    • November 19, 2026
    • Posted by: Ankit Jaiswal
    • Category: Market
    No Comments
    Albert David Analyst Review 2027: Sales Up 16% and Margins Recover, Profit Back in Black

    Albert David grew Q2 FY27 sales 16% to ₹100.83 crore and returned to a ₹2.88 crore profit after a loss a year ago, as operating margin rose to 11.6%. The Kolkata drug maker trades near book value. With no brokerage coverage, we review results, the business and risks.

    read more
  • Alembic Pharma Analyst Review 2027: Profit Up 81% and Guidance Raised, Stock Runs Past Targets

    • November 19, 2026
    • Posted by: Chaitanya Auti
    • Category: Market
    No Comments
    Alembic Pharma Analyst Review 2027: Profit Up 81% and Guidance Raised, Stock Runs Past Targets

    Alembic Pharma grew Q2 FY27 revenue 36% and profit 81% to ₹335 crore, led by a 77% jump in US sales, and raised FY27 growth guidance to 20% to 25%. The stock has run past Motilal Oswal’s ₹845 target. We review results, segments, valuation and risks.

    read more
  • Ajanta Pharma Analyst Review 2027: Profit Up 49% as Brokers Split Between ₹3,908 and ₹4,250

    • November 19, 2026
    • Posted by: Chaitanya Auti
    • Category: Market
    No Comments
    Ajanta Pharma Analyst Review 2027: Profit Up 49% as Brokers Split Between ₹3,908 and ₹4,250

    Ajanta Pharma grew Q2 FY27 revenue about 33% to ₹1,794 crore and profit about 49% to ₹388 crore, beating its margin guidance. PL Capital raised its target to ₹4,250 while Systematix moved to Hold. We review results, segments, valuation and risks.

    read more
  • 1
  • 2